Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (895)	6/12/1998 2:04:00 AM
From: Zvi Steinberg	Read Replies (4) of 1491

Here's the latest update on pharmos: BOL has finalized and approved everything regarding the co-marketing partner for Alrex. The necessary paperwork has been forwarded to Pharmos for final approval early in the week. Pharmos should complete the process quickly and it will made public soon. BOL uses IMS Research for their tracking of prescription data on all drugs so they can keep track on how they are doing as well as their competitors. BOLwill pay Pharmos via wire deposit at the end of each month. Pharmos burn rate will vary between $550k-$700k monthly. Pharmos will expect to receive each month in excess of $830k ($10mm annually). This is a conservative estimate (%50mm in annual sales * 20% = %10mm. Pharmos gets 29%, less fees and royalties to Dr. Bodor leaves approx. 20% for Pharmos). The current cash position of $5.5mm therefore should increase over time. The projected burn rate includes the upcoming phase 1 trials for Tamoxifen methiodide and phase 3 trials for Lotemax-T. Pharmos will not conduct phase 3 trials on HU-211 without a partner as they are too costly. Phase 2 trials for intestinal bowel disorder and other applications may be undertaken by the company if no partner is found, but this is an unknown at this time. Let it be stressed that the $10mm Pharmos will receive from sales is conservative, based on BOL's published estimates of sales they know they can attain. The real level of sales they expect is much higher, in fact 50%-70% higher. This is good as it shows that Pharmos should be on the right track for positive cash flow and won't be under the gun as far as cash is concerned. Best regards to all. Zvi

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next